New technology to characterize cancers: R&D, preclinical and clinical studies
RT MLPSEQA new technology to characterize cancersGene expression and fusion transcripts |
|||
The RT-MLPSeq custom solution from Biotrend USA and GeneXpath allows you to assess the mRNA expression level or the presence of fusion transcripts of 10 to 100 markers of interest of your choice. In research projects, preclinical and clinical studies, it is often necessary to obtain the gene expression or the presence of fusion transcripts of several dozen markers. At present, relative expression and fusion transcripts can only be analyzed with a small number of genes simultaneously, using complicated protocols. In addition, manipulation times are often very long, and solutions on the market are often expensive. Genexpath's custom panel solution enables you to select your markers of interest quickly and easily. We then provide you with a turnkey solution: an in Vitro test and a bioinformatic analysis after a NGS sequencing. These custom panels can be produced for any type of genome. We are at your disposal to produce panels of between ten and a hundred markers. |
|||
RT-MLPSEQ advantages | |||
|
|||
RT-MLPSeq technology is already being used in oncology diagnostic kits for: | |||
|
|||
RT-MLPSEQ: A simple and rapid protocol The robustness of our technology and our experience in diagnostics mean we can support you from R&D right through to companion diagnostics. |
|||
|
|||
Interested in more details? You can read more in our brochures! |
|||
|
|||
Should you have any questions or need assistance, feel free to contact our Business Development and Innovation Gael Gesbert. |
|||
|
|||